Olympus Restructures Medical Segments as Profit Slips Despite Steady Revenue

Olympus ( (JP:7733) ) has provided an update.

Olympus reported consolidated results for the fiscal year ended March 31, 2026, showing revenue of about ¥1.01 trillion from continuing operations and a sharp year-on-year decline in operating profit and net income, as margins compressed despite steady top-line growth. Foreign exchange had a mixed impact, with earlier yen weakness boosting revenue and profit, but later movements and higher costs, including selling, general and administrative expenses and other charges, weighed on profitability.

The company also overhauled its reporting structure, reorganizing the former Endoscopic and Therapeutic Solutions divisions into the new GIS and SIS segments and reallocating portions of corporate expenses, including basic research, to these units, with prior-period figures restated for comparability. This shift is aimed at improving transparency in segment performance and better aligning costs with revenue drivers, offering investors a clearer view of how Olympus’s core medical businesses are contributing to earnings under a more volatile currency and cost environment.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen1700.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

More about Olympus

Olympus is a medical technology company focused on endoscopy and therapeutic devices, with core operations now structured around its Gastrointestinal Solutions (GIS) and Surgical and Interventional Solutions (SIS) divisions. The group’s primary products serve gastrointestinal and surgical markets worldwide, and it allocates certain corporate research expenses into these operating units to better reflect underlying profitability.

Average Trading Volume: 6,650,062

Technical Sentiment Signal: Sell

Current Market Cap: Yen1730B

For detailed information about 7733 stock, go to TipRanks’ Stock Analysis page.